Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-05-06

Clinical Trial Update: A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis [Phase 2]

View source ↗

Summary

Phase 2 randomized study evaluating two concentrations of A-101 for seborrheic keratosis completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • A-101

Snippet

Sponsor: Aclaris Therapeutics, Inc. | Conditions: Seborrheic Keratosis | Phase 2 | Status: COMPLETED | Results posted: 2019-05-06